Pfizer share price
NSE: PFIZERPharma & HealthcareDrug Manufacturers - General
Pfizer at a glance
Pfizer (NSE: PFIZER) closed at ₹3,712.10 on 22 Oct 2026, down 0.93% on the day. With a market capitalisation of ₹16,982 Cr, it ranks 387th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.
At its last close the stock traded at 23.5× trailing earnings, against a return on equity of 33.2% in FY09. Over the past year the share price has fallen 30.9%. Its 52-week range is ₹3,681.50 (22 Oct 2026) to ₹5,446.00 (23 Oct 2025); the last close is 31.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹653 Cr (+8.3% year on year) and net profit ₹204 Cr (+6.6%), on a standalone basis. Promoters held 63.92% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹16,982 CrRank 387 on NSE
- P/E (trailing)
- 23.5×
- Price to book
- 1.55×FY09
- EPS (TTM)
- ₹160.70to Q1 FY27
- ROE
- 33.2%FY09
- ROCE
- 33.1%FY09
- Debt to equity
- 0FY09
- Net profit margin
- 40.9%FY09
- Book value / share
- ₹301.94FY09
- Dividend payout
- 12.5%FY09
- 52-week high
- ₹5,446.0023 Oct 2025
- 52-week low
- ₹3,681.5022 Oct 2026
- 1-year return
- −30.9%
- RSI (14-day)
- 33.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.93% | −5.4% | −8.0% | −20.2% | −30.9% |
Pfizer quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹589 Cr | ₹538 Cr | ₹592 Cr | ₹603 Cr | ₹642 Cr | ₹645 Cr | ₹629 Cr | ₹653 Cr |
| Revenue YoY | +2.3% | −0.4% | +8.3% | +7.1% | +9.1% | +19.9% | +6.3% | +8.3% |
| Net profit | ₹158 Cr | ₹128 Cr | ₹331 Cr | ₹192 Cr | ₹189 Cr | ₹142 Cr | ₹200 Cr | ₹204 Cr |
| Net profit YoY | +6.3% | −1.8% | +85.0% | +27.2% | +19.4% | +11.2% | −39.6% | +6.6% |
| Net margin | 26.9% | 23.7% | 55.9% | 31.8% | 29.4% | 22.0% | 31.8% | 31.3% |
| EPS | ₹34.61 | ₹27.89 | ₹72.34 | ₹41.91 | ₹41.32 | ₹31.01 | ₹43.68 | ₹44.69 |
Pfizer financials
| Item | FY07 | FY08 | FY09 |
|---|---|---|---|
| Revenue | ₹734 Cr | ₹736 Cr | ₹733 Cr |
| Operating profit | ₹186 Cr | ₹467 Cr | ₹207 Cr |
| Net profit | ₹106 Cr | ₹340 Cr | ₹300 Cr |
| EPS (₹) | ₹36.00 | ₹114.00 | ₹100.00 |
| Cash from operations | ₹123 Cr | ₹16 Cr | ₹238 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹406 Cr | ₹650 Cr | ₹901 Cr |
Pfizer shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% | 63.92% |
| Foreign institutions | 2.18% | 2.39% | 2.60% | 2.71% | 2.81% | 1.65% |
| Domestic institutions | 17.10% | 17.23% | 17.10% | 17.05% | 16.89% | 17.80% |
| Non-institutions | 16.79% | 16.45% | 16.37% | 16.32% | 16.37% | 16.63% |
Pfizer vs peers
The listed Pharma & Healthcare companies nearest to Pfizer by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| COHANCECohance Lifesciences | ₹460.30 | −0.25% | −46.9% | ₹17,610 Cr | 98.6 | — |
| SHILPAMEDShilpa Medicare | ₹880.90 | +4.74% | +150.3% | ₹17,229 Cr | 70.9 | — |
| PFIZERPfizer | ₹3,712.10 | −0.93% | −30.9% | ₹16,982 Cr | 23.5 | — |
| CAPLIPOINTCaplin Point Laboratories | ₹2,227.80 | +0.35% | +12.9% | ₹16,934 Cr | — | — |
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,848 Cr | 25.3 | — |
| ONESOURCEOnesource Specialty Pharma | ₹1,378.00 | +1.64% | −25.1% | ₹15,798 Cr | — | — |
| ALIVUSAlivus Life Sciences | ₹1,272.00 | +0.82% | +37.5% | ₹15,612 Cr | 27.7 | — |
Ask anything about Pfizer
Pivot answers on the live chart with evidence you can check, and tests strategies against PFIZER's own history. Try: “Why has PFIZER moved over the last three months?” · “Backtest a 50-day moving-average crossover on PFIZER over five years” · “Compare PFIZER with COHANCE on margins and valuation”
Frequently asked questions about Pfizer
What is the share price of Pfizer today?
Pfizer (NSE: PFIZER) last closed at ₹3,712.10 on 22 Oct 2026. Its 52-week high is ₹5,446.00 and its 52-week low is ₹3,681.50.
What is the market cap of Pfizer?
Pfizer's market capitalisation is ₹16,982 Cr (₹16,982 Cr) at the 22 Oct 2026 close, ranking 387th among the NSE companies Pivot tracks.
What is the P/E ratio of Pfizer?
Pfizer trades at a trailing P/E of 23.5. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 70.9.
What is the ROE and ROCE of Pfizer?
Return on equity was 33.2% in FY09 and return on capital employed was 33.1% in FY09 (consolidated figures).
Is Pfizer a debt-free company?
Pfizer is close to debt-free: its debt-to-equity ratio was 0 in FY09.
What were Pfizer's latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Pfizer reported revenue of ₹653 Cr, +8.3% year on year, and net profit of ₹204 Cr, +6.6% year on year.
How has Pfizer stock performed over the last year?
Pfizer's share price has fallen 30.9% over the past year, −20.2% over three months and −8.0% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Pfizer?
As of 30 Jun 2026: promoters 63.92%, foreign institutions 1.65%, domestic institutions 17.80%, non-institutions 16.63%.
Who are Pfizer's competitors?
The listed Pharma & Healthcare companies closest to Pfizer by market cap are Cohance Lifesciences, Shilpa Medicare, Caplin Point Laboratories, Eris Lifesciences, Onesource Specialty Pharma and Alivus Life Sciences.
Is Pfizer a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Pfizer's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on PFIZER against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with P · all NSE stocks · this page as text